

8.Literaturverzeichnis

1. Newton, J. N., Swerdlow, A. J., dos, S. S., I, Vessey, M. P., Grahame-Smith, D. G., Primates, P., and Reynolds, D. J. The epidemiology of carcinoid tumours in England and Scotland. *Br.J.Cancer*, 70: 939-942, 1994.
2. Modlin, I. M., Lye, K. D., and Kidd, M. A 5-decade analysis of 13,715 carcinoid tumors. *Cancer*, 97: 934-959, 2003.
3. Wick, M. R. Neuroendocrine neoplasia. Current concepts. *Am.J.Clin.Pathol*, 113: 331-335, 2000.
4. Schmitt-Graff, A., Nitschke, R., and Wiedenmann, B. [Gastroenteropancreatic neuroendocrine/endocrine tumors. Current pathologic-diagnostic view]. *Pathologe*, 22: 105-113, 2001.
5. Wiedenmann, B., John, M., Ahnert-Hilger, G., and Riecken, E. O. Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system. *J.Mol.Med*, 76: 637-647, 1998.
6. Lubarsch O. Ueber den primären Krebs des Ileum, nebst Bemerkungen über das gleichzeitige Vorkommen von Krebs und Tuberkulose. *Virchows Archiv*, 111: 280-317, 1888.
7. Oberndorfer S. Karzinoide Tumoren des Dünndarms. *Frankf Z Pathol*, 1: 425-429, 1907.
8. Ransom W. A case of primary carcinoma in the ileum. *Lancet*, 1020-1021, 1890.
9. WILLIAMS ED and SANDLER M. The classification of carcinoid tumours. *Lancet*, 1: 238-239, 1963.
10. Berge, T. and Linell, F. Carcinoid tumours. Frequency in a defined population during a 12-year period. *Acta Pathol.Microbiol.Scand.[A]*, 84: 322-330, 1976.
11. Capella, C., Heitz, P. U., Hofler, H., Solcia, E., and Kloppel, G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. *Virchows Archiv*, 452: 547-560, 1995.
12. Solcia, E., Klöppel G., and Sobin, L. H. *Histological Typing of Endocrine Tumors*, 2nd ed. World Health Organization, 2000.
13. Rindi, G., Bordi, C., Rappel, S., La Rosa, S., Stolte, M., and Solcia, E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. *World J.Surg.*, 20: 168-172, 1996.
14. Rindi, G., Luinetti, O., Cornaggia, M., Capella, C., and Solcia, E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. *Gastroenterology*, 104: 994-1006, 1993.
15. Pape, U. F., Bohmig, M., Tiling, N., and Wiedenmann, B. Diagnostik und Therapie gastroenteropankreatischer neuroendokriner Tumore aus internistischer Sicht. *Onkologe*, 6: 624-633, 2000.

16. Jensen, R. T. Pancreatic endocrine tumors: recent advances. *Ann Oncol.*, *10 Suppl 4*: 170-176, 1999.
17. Seregni, E., Ferrari, L., Bajetta, E., Martinetti, A., and Bombardieri, E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. *Ann Oncol.*, *12 Suppl 2*: S69-S72, 2001.
18. Oberg, K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. *Curr.Opin.Oncol.*, *14*: 38-45, 2002.
19. Stridsberg, M., Oberg, K., Li, Q., Engstrom, U., and Lundqvist, G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. *J.Endocrinol.*, *144*: 49-59, 1995.
20. Ricke, J. and Klose, K. J. Imaging procedures in neuroendocrine tumours. *Digestion*, *62 Suppl 1*: 39-44, 2000.
21. Scherubl, H., Bader, M., Fett, U., Hamm, B., Schmidt-Gayk, H., Koppenhagen, K., Dop, F. J., Riecken, E. O., and Wiedenmann, B. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. *Gastroenterology*, *105*: 1705-1709, 1993.
22. Wiedenmann, B., Bader, H. M., Scherubl, H., Fett, U., Zimmer, T., Hamm, B., Koppenhagen, K., and Riecken, E. O. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy. *Semin.Oncol.*, *21*: 29-32, 1994.
23. Kwekkeboom, D. J. and Krenning, E. P. Somatostatin receptor scintigraphy in patients with carcinoid tumors. *World J.Surg.*, *20*: 157-161, 1996.
24. Plockinger, U., Rindi, G., Arnold, R., Eriksson, B., Krenning, E. P., de Herder, W. W., Goede, A., Caplin, M., Oberg, K., Reubi, J. C., Nilsson, O., Delle, F. G., Ruszniewski, P., Ahlman, H., and Wiedenmann, B. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). *Neuroendocrinology*, *80*: 394-424, 2004.
25. Plath, T., Hocker, M., Riecken, E. O., Wang, T. C., Wiedenmann, B., and Rosewicz, S. Interferon-alpha inhibits chromogranin A promoter activity in neuroendocrine pancreatic cancer cells. *FEBS Lett.*, *458*: 378-382, 1999.
26. Detjen, K. M., Welzel, M., Farwig, K., Brembeck, F. H., Kaiser, A., Riecken, E. O., Wiedenmann, B., and Rosewicz, S. Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. *Gastroenterology*, *118*: 735-748, 2000.
27. von Marschall, Z., Scholz, A., Cramer, T., Schafer, G., Schirner, M., Oberg, K., Wiedenmann, B., Hocker, M., and Rosewicz, S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. *J.Natl.Cancer Inst.*, *95*: 437-448, 2003.

28. Oberg, K. Interferon in the management of neuroendocrine GEP-tumors: a review. *Digestion*, 62 Suppl 1: 92-97, 2000.
29. Oberg, K. Future aspects of somatostatin-receptor-mediated therapy. *Neuroendocrinology*, 80 Suppl 1: 57-61, 2004.
30. Reisine, T. and Bell, G. I. Molecular biology of somatostatin receptors. *Endocr.Rev.*, 16: 427-442, 1995.
31. Patel, Y. C., Greenwood, M. T., Panetta, R., Demchyshyn, L., Niznik, H., and Srikant, C. B. The somatostatin receptor family. *Life Sci.*, 57: 1249-1265, 1995.
32. Garcia, d. I. T., Wass, J. A., and Turner, H. E. Antiangiogenic effects of somatostatin analogues. *Clin.Endocrinol.(Oxf)*, 57: 425-441, 2002.
33. von Wichert, G., Jehle, P. M., Hoeflich, A., Koschnick, S., Dralle, H., Wolf, E., Wiedenmann, B., Boehm, B. O., Adler, G., and Seufferlein, T. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. *Cancer Res.*, 60: 4573-4581, 2000.
34. Oberg, K., Astrup, L., Eriksson, B., Falkmer, S. E., Falkmer, U. G., Gustafsen, J., Haglund, C., Knigge, U., Vatn, M. H., and Valimaki, M. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. *Acta Oncol.*, 43: 617-625, 2004.
35. Faiss, S., Pape, U. F., Bohmig, M., Dorffel, Y., Mansmann, U., Golder, W., Riecken, E. O., and Wiedenmann, B. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. *J.Clin.Oncol.*, 21: 2689-2696, 2003.
36. Moertel, C. G., Kvols, L. K., O'Connell, M. J., and Rubin, J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. *Cancer*, 68: 227-232, 1991.
37. Mitry, E., Baudin, E., Ducreux, M., Sabourin, J. C., Rufie, P., Aparicio, T., Aparicio, T., Lasser, P., Elias, D., Duvillard, P., Schlumberger, M., and Rougier, P. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. *Br.J.Cancer*, 81: 1351-1355, 1999.
38. Moertel, C. G. An odyssey in the land of small tumors. *J.Clin.Oncol.*, 5: 1503-1522, 1987.
39. Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., and Klaassen, D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. *N.Engl.J.Med*, 326: 519-523, 1992.
40. Rougier, P. and Mitry, E. Chemotherapy in the treatment of neuroendocrine malignant tumors. *Digestion*, 62 Suppl 1: 73-78, 2000.

41. Waldherr, C., Pless, M., Maecke, H. R., Schumacher, T., Crazzolara, A., Nitzsche, E. U., Haldemann, A., and Mueller-Brand, J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. *J.Nucl.Med*, 43: 610-616, 2002.
42. Levi, F., Te, V. C., Randimbison, L., Rindi, G., and La Vecchia, C. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. *Br.J.Cancer*, 83: 952-955, 2000.
43. Quaedvlieg, P. F., Visser, O., Lamers, C. B., Janssen-Heijen, M. L., and Taal, B. G. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. *Ann Oncol.*, 12: 1295-1300, 2001.
44. Hemminki, K. and Li, X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. *Cancer*, 92: 2204-2210, 2001.
45. Soga, J. Statistical evaluation of 2001 carcinoid cases with metastases, collected from literature: a comparative study between ordinary carcinoids and atypical varieties. *J.Exp.Clin.Cancer Res.*, 17: 3-12, 1998.
46. Pape, U. F., Bohmig, M., Berndt, U., Tiling, N., Wiedenmann, B., and Plockinger, U. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center. *Ann N.Y.Acad.Sci.*, 1014: 222-233, 2004.
47. Zyromski, N. J., Kendrick, M. L., Nagorney, D. M., Grant, C. S., Donohue, J. H., Farnell, M. B., Thompson, G. B., Farley, D. R., and Sarr, M. G. Duodenal carcinoid tumors: how aggressive should we be? *J.Gastrointest.Surg.*, 5: 588-593, 2001.
48. Onaitis, M. W., Kirshbom, P. M., Hayward, T. Z., Quayle, F. J., Feldman, J. M., Seigler, H. F., and Tyler, D. S. Gastrointestinal carcinoids: characterization by site of origin and hormone production. *Ann Surg.*, 232: 549-556, 2000.
49. Shebani, K. O., Souba, W. W., Finkelstein, D. M., Stark, P. C., Elgadi, K. M., Tanabe, K. K., and Ott, M. J. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. *Ann Surg.*, 229: 815-821, 1999.
50. Janson, E. T., Holmberg, L., Stridsberg, M., Eriksson, B., Theodorsson, E., Wilander, E., and Oberg, K. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. *Ann Oncol.*, 8: 685-690, 1997.
51. Van Gompel, J. J., Sippel, R. S., Warner, T. F., and Chen, H. Gastrointestinal carcinoid tumors: factors that predict outcome. *World J.Surg.*, 28: 387-392, 2004.
52. Maggard, M. A., O'Connell, J. B., and Ko, C. Y. Updated population-based review of carcinoid tumors. *Ann Surg.*, 240: 117-122, 2004.
53. Kirshbom, P. M., Kherani, A. R., Onaitis, M. W., Feldman, J. M., and Tyler, D. S. Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. *Surgery*, 124: 1063-1070, 1998.

54. Skuladottir, H., Hirsch, F. R., Hansen, H. H., and Olsen, J. H. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. *Lung Cancer*, 37: 127-135, 2002.
55. Sprenger A., Wied M., and Mueller H.H. Prognostic factors in patients with neuroendocrine gastroenteropancreatic tumors [abstr]. *Gastroenterology*, 120: 2743, 2001.
56. Yantiss, R. K., Odze, R. D., Farraye, F. A., and Rosenberg, A. E. Solitary versus multiple carcinoid tumors of the ileum: a clinical and pathologic review of 68 cases. *Am.J.Surg.Pathol.*, 27: 811-817, 2003.
57. Burke, A. P., Thomas, R. M., Elsayed, A. M., and Sobin, L. H. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. *Cancer*, 79: 1086-1093, 1997.
58. Chu, Q. D., Hill, H. C., Douglass, H. O., Jr., Driscoll, D., Smith, J. L., Nava, H. R., and Gibbs, J. F. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. *Ann Surg.Oncol.*, 9: 855-862, 2002.
59. Soreide, J. A., van Heerden, J. A., Thompson, G. B., Schleck, C., Ilstrup, D. M., and Churchward, M. Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. *World J.Surg.*, 24: 1431-1436, 2000.
60. Toth-Fejel, S. and Pommier, R. F. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors. *Am.J.Surg.*, 187: 575-579, 2004.
61. Feldman, J. M. Carcinoid tumors and the carcinoid syndrome. *Curr.Probl.Surg.*, 26: 835-885, 1989.
62. Hellman, P., Lundstrom, T., Ohrvall, U., Eriksson, B., Skogseid, B., Oberg, K., Tiensuu, J. E., and Akerstrom, G. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. *World J.Surg.*, 26: 991-997, 2002.
63. Schindl, M., Kaczirek, K., Passler, C., Kaserer, K., Prager, G., Scheuba, C., Raderer, M., and Niederle, B. Treatment of small intestinal neuroendocrine tumors: is an extended multimodal approach justified? *World J.Surg.*, 26: 976-984, 2002.
64. Lo, C. Y., van Heerden, J. A., Thompson, G. B., Grant, C. S., Soreide, J. A., and Harmsen, W. S. Islet cell carcinoma of the pancreas. *World J.Surg.*, 20: 878-883, 1996.
65. Pelley, R. J. and Bukowski, R. M. Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors. *Curr.Opin.Oncol.*, 11: 32-37, 1999.
66. Kolby, L., Persson, G., Franzen, S., and Ahren, B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. *Br.J.Surg.*, 90: 687-693, 2003.

67. Arnold, R., Trautmann, M. E., Creutzfeldt, W., Benning, R., Benning, M., Neuhaus, C., Jurgensen, R., Stein, K., Schafer, H., Bruns, C., and Dennler, H. J. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. *Gut*, 38: 430-438, 1996.
68. Frank, M., Klose, K. J., Wied, M., Ishaque, N., Schade-Brittinger, C., and Arnold, R. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. *Am.J.Gastroenterol.*, 94: 1381-1387, 1999.
69. Ducreux, M., Ruszniewski, P., Chayvialle, J. A., Blumberg, J., Cloarec, D., Michel, H., Raymond, J. M., Dupas, J. L., Gouerou, H., Jian, R., Genestin, E., Hammel, P., and Rougier, P. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. *Am.J.Gastroenterol.*, 95: 3276-3281, 2000.
70. Grama, D., Eriksson, B., Martensson, H., Cedermark, B., Ahren, B., Kristoffersson, A., Rastad, J., Oberg, K., and Akerstrom, G. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. *World J.Surg.*, 16: 632-639, 1992.
71. Rindi, G., Azzoni, C., La Rosa, S., Klersy, C., Paolotti, D., Rappel, S., Stolte, M., Capella, C., Bordi, C., and Solcia, E. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. *Gastroenterology*, 116: 532-542, 1999.
72. McCusker, M. E., Cote, T. R., Clegg, L. X., and Sobin, L. H. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. *Cancer*, 94: 3307-3312, 2002.